What is secondary AML?
Secondary AML (sAML) is a type of AML that develops due to previous cancer or non-cancer treatments or certain blood cell disorders.
sAML consists of different subtypes, 2 of which are known as therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). sAML has traditionally been treated with chemotherapy.
Watch the video below to learn more about sAML subtypes t-AML and AML-MRC.
Treatment for t-AML and AML-MRC
sAML has traditionally been treated with chemotherapy. VYXEOS (vix-e-ose) is an advancement in chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed sAML: t-AML or AML-MRC. For these types of sAML, VYXEOS is the only chemotherapy that combines 2 currently used, effective chemotherapies into tiny, bubble-like carriers called liposomes, which carry the drugs to the bone marrow.